Evidence map›Paper›PMID 42636371›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Convergent roles of GDF-15 in mechanotransduction, vascular disorganization, and immune suppression in melanoma.

Yu-Chi Chen, Vishnu Sravan Bollu, Sina Kheirabadi, Kyle LaPenna, Arthur Berg, Pingnian He, Todd D Schell, Amir Sheikhi, Erdem D Tabdanov, Gavin P Robertson

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yu-Chi ChenDepartment of Molecular and Precision Medicine, College of Medicine, The Pennsylvania State University,Hershey, PA 17033.
Vishnu Sravan BolluDepartment of Molecular and Precision Medicine, College of Medicine, The Pennsylvania State University,Hershey, PA 17033.
Sina KheirabadiDepartment of Chemical Engineering, College of Engineering, The Pennsylvania State University, University Park, PA 16802.ORCID 0000-0003-0191-1546
Kyle LaPennaDepartment of Cell and Biological Systems, College of Medicine, The Pennsylvania State University, Hershey, PA 17033.
Arthur BergDepartment of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA 17033.ORCID 0000-0002-4097-7348
Pingnian HeDepartment of Cell and Biological Systems, College of Medicine, The Pennsylvania State University, Hershey, PA 17033.
Todd D SchellDepartment of Cell and Biological Systems, College of Medicine, The Pennsylvania State University, Hershey, PA 17033.ORCID 0000-0002-6788-6518
Amir SheikhiDepartment of Chemical Engineering, College of Engineering, The Pennsylvania State University, University Park, PA 16802.ORCID 0000-0002-4495-6675
Erdem D TabdanovDepartment of Cell and Biological Systems, College of Medicine, The Pennsylvania State University, Hershey, PA 17033.ORCID 0000-0003-2673-112X
Gavin P RobertsonDepartment of Molecular and Precision Medicine, College of Medicine, The Pennsylvania State University,Hershey, PA 17033.ORCID 0000-0003-0152-2997

Funding

Red blood cell released ATP in disturbed blood flow-initiated site specific vascular inflammation and atherosclerosisR01HL144620 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HE, PINGNIAN · 2019 to 2022
$3.1M
Mechanisms of cognitive impairment caused by atherosclerosis and red blood cell released ATPR01NS139128 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Prosenjit Bagchi, PINGNIAN HE · 2024 to 2026
$2.5M
Chocolate Tour Cancer Research Fund N/ADorothy Foehr Huck and J. Lloyd Huck Early Career Chair N/AForeman Foundation for Melanoma Research N/AMeghan Rose Bradley Foundation (Meghan Bradley Foundation Inc.) N/AMike Geltrude Foundation (The Mike Geltrude Foundation) N/ANCI NIH HHS R01CA241148-03NHLBI NIH HHS HL144620NHLBI NIH HHS R01 HL144620NIH NHLB R01HL167939NIH RO1CA241148-0252-ExtNINDS NIH HHS R01NS139128Sherwin Williams Activities Committee Fund N/A
6 · The paper itself

Abstract

Melanoma, particularly in its advanced forms, remains one of the most lethal skin cancers, with limited effective treatments for both common cutaneous subtypes and rarer variants such as acral melanoma. The effects of the extracellular matrix (ECM) and other cancer-cell extrinsic processes on melanoma development remain underexplored. This study identifies growth differentiation factor-15 (GDF-15) as a mechanosensing-regulated driver of melanoma pathogenesis across melanoma types. GDF-15 is shown here to be mechanically induced by ECM rigidity and compressive forces occurring during metastatic progression, leading to significantly elevated levels in both cutaneous and acral melanoma cells. In this study, ECM rigidity was recapitulated using cell-adhesive gelatin methacryloyl (GelMA) hydrogel microparticles (microgels) with tunable stiffness, providing a biomimetic platform to investigate how mechanical cues in the tumor microenvironment regulate GDF-15 expression in melanoma. A previously unrecognized synergy between GDF-15 and inflammatory factors commonly present in tumors was identified and found to promote a disorganized, hyperpermeable vasculature, thereby facilitating tumor nutrient access and impeding effective immune cell infiltration. GDF-15 knockdown reduced the intratumoral hemorrhage phenotype, indicating a causal role. GDF-15 also functions by directly suppressing natural killer (NK) cell-mediated cytotoxicity, revealing a second cooperating mechanism of immune evasion. These effects position GDF-15 as a key node linking mechanical stress, co-operation with inflammatory factors, abnormal vascular development, and immune dysfunction, thereby converging on pathways and processes relevant to melanoma progression and treatment.

Indexed as

Growth Differentiation Factor 15Mechanotransduction, CellularMelanomaSkin NeoplasmsAnimalsCell Line, TumorExtracellular MatrixHumansNeovascularization, PathologicTumor MicroenvironmentGDF15 protein, humanGrowth Differentiation Factor 15acral melanomacutaneous melanomaECM rigidityGelMAgrowth differentiation factor-15

Identifiers

PMID42636371
PMCPMC13535137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.